STOCK TITAN

Molecular Templates, Inc. - $MTEM STOCK NEWS

Welcome to our dedicated page for Molecular Templates news (Ticker: $MTEM), a resource for investors and traders seeking the latest updates and insights on Molecular Templates stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Molecular Templates's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Molecular Templates's position in the market.

Rhea-AI Summary
Molecular Templates, Inc. (Nasdaq: MTEM) reported Q2 2023 financial results, including a net loss of $10.9 million and revenues of $6.9 million. The company highlighted the progress in its clinical programs and collaborations, such as the private placement and debt restructuring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
-
Rhea-AI Summary
Molecular Templates, Inc. (Nasdaq: MTEM) announced executive management changes to implement its next phase of development. Dr. Gabriela Gruia will assume the role of interim Chief Medical Officer, Jason Kim will become President and Chief Financial Officer, Kristen Quigley will be the Chief Operating Officer, and Dr. Grace Kim will take on the role of Chief Strategy Officer and Head of Investor Relations. These changes aim to better enable Molecular Templates to execute on its clinical and corporate objectives, with a focus on oncology drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
management
-
Rhea-AI Summary
Molecular Templates, Inc. has entered into a securities purchase agreement to raise up to $40 million in a private placement. The financing is being led by existing investor BVF Partners LP and includes other institutional investors. The first tranche of $20 million is expected to close on July 17, 2023, with an additional $20 million available in a second tranche if certain stock price and trading levels are achieved within a 12-month period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
none
Molecular Templates, Inc.

Nasdaq:MTEM

MTEM Rankings

MTEM Stock Data

10.60M
3.28M
3.96%
58.79%
0.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
AUSTIN

About MTEM

molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.